Evaluation of the anti-inflammatory and cytotoxic effects of anthraquinones and anthracenes derivatives in human leucocytes

Rong Fu Chen, Yuh Chiang Shen, Hsu Shan Huang, Jyh Fei Liao, Li Kang Ho, Yueh Ching Chou, Wen Yen Wang, Chieh Fu Chen

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A variety of anthracene- and anthraquinone-related derivatives, modified from three types of lead structures, including 9-acyloxy 1,5-dichloroanthracene (type I), 1,5-bisacyloxy-anthraquinones with O-linked substituents (type II) and 1,5-bisacyloxy-anthraquinones with S-linked substituents (type III), were synthesized and evaluated by an in-vitro bioassay for their anti-inflammatory and cytotoxic effects in human leucocytes. Among these derivatives, type I compounds displayed potent anti-inflammatory activity against phorbol-12-myristate-13-acetate (PMA)-induced superoxide anion production, a bio-marker of inflammatory mediator production by neutrophils, with 50% inhibition (IC50) concentrations (μM) for compounds 1f, 1g, 1h and 1m being 13.8 ± 3.0, 6.3 ± 4.1, 33.2 ± 1.3 and 33.9 ± 5.7, respectively. Type II and type III derivatives (i.e., 1,5-bisacyloxy anthraquinone-related compounds) and the reference compound, emodin, exhibited relatively minor (20-40%) inhibitory effect against superoxide production by neutrophils. Furthermore, none of these compounds showed a significant cytotoxic effect in human neutrophils. In conclusion, these results suggest that compounds modified from 9-acyloxy 1,5-dichloroanthracence (type I) are more powerful than the other two types as anti-inflammatory drugs. This is the first demonstration that derivatives modified from anthracenes or anthraquinones possess anti-inflammatory activity with no significant cytotoxicity in human neutrophils.

Original languageEnglish
Pages (from-to)915-919
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume56
Issue number7
DOIs
Publication statusPublished - Jul 2004
Externally publishedYes

Fingerprint

Anthracenes
Anthraquinones
Leukocytes
Anti-Inflammatory Agents
Neutrophils
Superoxides
Emodin
Biological Assay
Inhibitory Concentration 50
Acetates
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Evaluation of the anti-inflammatory and cytotoxic effects of anthraquinones and anthracenes derivatives in human leucocytes. / Chen, Rong Fu; Shen, Yuh Chiang; Huang, Hsu Shan; Liao, Jyh Fei; Ho, Li Kang; Chou, Yueh Ching; Wang, Wen Yen; Chen, Chieh Fu.

In: Journal of Pharmacy and Pharmacology, Vol. 56, No. 7, 07.2004, p. 915-919.

Research output: Contribution to journalArticle

Chen, Rong Fu ; Shen, Yuh Chiang ; Huang, Hsu Shan ; Liao, Jyh Fei ; Ho, Li Kang ; Chou, Yueh Ching ; Wang, Wen Yen ; Chen, Chieh Fu. / Evaluation of the anti-inflammatory and cytotoxic effects of anthraquinones and anthracenes derivatives in human leucocytes. In: Journal of Pharmacy and Pharmacology. 2004 ; Vol. 56, No. 7. pp. 915-919.
@article{1419b60c20b640d8b1671bd716bb1322,
title = "Evaluation of the anti-inflammatory and cytotoxic effects of anthraquinones and anthracenes derivatives in human leucocytes",
abstract = "A variety of anthracene- and anthraquinone-related derivatives, modified from three types of lead structures, including 9-acyloxy 1,5-dichloroanthracene (type I), 1,5-bisacyloxy-anthraquinones with O-linked substituents (type II) and 1,5-bisacyloxy-anthraquinones with S-linked substituents (type III), were synthesized and evaluated by an in-vitro bioassay for their anti-inflammatory and cytotoxic effects in human leucocytes. Among these derivatives, type I compounds displayed potent anti-inflammatory activity against phorbol-12-myristate-13-acetate (PMA)-induced superoxide anion production, a bio-marker of inflammatory mediator production by neutrophils, with 50{\%} inhibition (IC50) concentrations (μM) for compounds 1f, 1g, 1h and 1m being 13.8 ± 3.0, 6.3 ± 4.1, 33.2 ± 1.3 and 33.9 ± 5.7, respectively. Type II and type III derivatives (i.e., 1,5-bisacyloxy anthraquinone-related compounds) and the reference compound, emodin, exhibited relatively minor (20-40{\%}) inhibitory effect against superoxide production by neutrophils. Furthermore, none of these compounds showed a significant cytotoxic effect in human neutrophils. In conclusion, these results suggest that compounds modified from 9-acyloxy 1,5-dichloroanthracence (type I) are more powerful than the other two types as anti-inflammatory drugs. This is the first demonstration that derivatives modified from anthracenes or anthraquinones possess anti-inflammatory activity with no significant cytotoxicity in human neutrophils.",
author = "Chen, {Rong Fu} and Shen, {Yuh Chiang} and Huang, {Hsu Shan} and Liao, {Jyh Fei} and Ho, {Li Kang} and Chou, {Yueh Ching} and Wang, {Wen Yen} and Chen, {Chieh Fu}",
year = "2004",
month = "7",
doi = "10.1211/0022357023781",
language = "English",
volume = "56",
pages = "915--919",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "7",

}

TY - JOUR

T1 - Evaluation of the anti-inflammatory and cytotoxic effects of anthraquinones and anthracenes derivatives in human leucocytes

AU - Chen, Rong Fu

AU - Shen, Yuh Chiang

AU - Huang, Hsu Shan

AU - Liao, Jyh Fei

AU - Ho, Li Kang

AU - Chou, Yueh Ching

AU - Wang, Wen Yen

AU - Chen, Chieh Fu

PY - 2004/7

Y1 - 2004/7

N2 - A variety of anthracene- and anthraquinone-related derivatives, modified from three types of lead structures, including 9-acyloxy 1,5-dichloroanthracene (type I), 1,5-bisacyloxy-anthraquinones with O-linked substituents (type II) and 1,5-bisacyloxy-anthraquinones with S-linked substituents (type III), were synthesized and evaluated by an in-vitro bioassay for their anti-inflammatory and cytotoxic effects in human leucocytes. Among these derivatives, type I compounds displayed potent anti-inflammatory activity against phorbol-12-myristate-13-acetate (PMA)-induced superoxide anion production, a bio-marker of inflammatory mediator production by neutrophils, with 50% inhibition (IC50) concentrations (μM) for compounds 1f, 1g, 1h and 1m being 13.8 ± 3.0, 6.3 ± 4.1, 33.2 ± 1.3 and 33.9 ± 5.7, respectively. Type II and type III derivatives (i.e., 1,5-bisacyloxy anthraquinone-related compounds) and the reference compound, emodin, exhibited relatively minor (20-40%) inhibitory effect against superoxide production by neutrophils. Furthermore, none of these compounds showed a significant cytotoxic effect in human neutrophils. In conclusion, these results suggest that compounds modified from 9-acyloxy 1,5-dichloroanthracence (type I) are more powerful than the other two types as anti-inflammatory drugs. This is the first demonstration that derivatives modified from anthracenes or anthraquinones possess anti-inflammatory activity with no significant cytotoxicity in human neutrophils.

AB - A variety of anthracene- and anthraquinone-related derivatives, modified from three types of lead structures, including 9-acyloxy 1,5-dichloroanthracene (type I), 1,5-bisacyloxy-anthraquinones with O-linked substituents (type II) and 1,5-bisacyloxy-anthraquinones with S-linked substituents (type III), were synthesized and evaluated by an in-vitro bioassay for their anti-inflammatory and cytotoxic effects in human leucocytes. Among these derivatives, type I compounds displayed potent anti-inflammatory activity against phorbol-12-myristate-13-acetate (PMA)-induced superoxide anion production, a bio-marker of inflammatory mediator production by neutrophils, with 50% inhibition (IC50) concentrations (μM) for compounds 1f, 1g, 1h and 1m being 13.8 ± 3.0, 6.3 ± 4.1, 33.2 ± 1.3 and 33.9 ± 5.7, respectively. Type II and type III derivatives (i.e., 1,5-bisacyloxy anthraquinone-related compounds) and the reference compound, emodin, exhibited relatively minor (20-40%) inhibitory effect against superoxide production by neutrophils. Furthermore, none of these compounds showed a significant cytotoxic effect in human neutrophils. In conclusion, these results suggest that compounds modified from 9-acyloxy 1,5-dichloroanthracence (type I) are more powerful than the other two types as anti-inflammatory drugs. This is the first demonstration that derivatives modified from anthracenes or anthraquinones possess anti-inflammatory activity with no significant cytotoxicity in human neutrophils.

UR - http://www.scopus.com/inward/record.url?scp=3042855151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042855151&partnerID=8YFLogxK

U2 - 10.1211/0022357023781

DO - 10.1211/0022357023781

M3 - Article

VL - 56

SP - 915

EP - 919

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 7

ER -